Dublin, Dec. 02, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, Application, Technology, and End User - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The global molecular diagnostics market is projected to reach $24,228.0 million by 2031 from $10,914.6 million in 2020, at a CAGR of 7.38% during the forecast period 2021-2031.
Market Report Coverage - Molecular Diagnostics
Products (Kits and Consumables, Systems, Software and Other Products)
Testing Location (Laboratory Testing and Point-of-Care (POC) Testing)
Application (Core Molecular Diagnostics, Reproductive Genetics, Companion Diagnostics (CDx), Liquid Biopsy, and Others)
Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing, Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, In-situ Hybridization (ISH), Immunohistochemistry (IHC) and Other Technologies)
End User (Hospitals, Diagnostics Centers, Out-Patient Clinics/General Practitioners, Research Laboratories, and Other End Users)
North America: U.S., Canada
Europe: Germany, France, Italy, U.K., Spain, and Rest-of-Europe
Asia-Pacific: Japan, China, India, Australia, Singapore, and Rest-of-Asia-Pacific
Latin America: Brazil, Mexico, Rest-of-Latin America
Key Companies Profiled
Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Guardant Health, HTG Molecular Diagnostics, Inc., Illumina, Inc., Invivoscribe, Inc., ICON plc, LungLife AI, Inc., QIAGEN, QuantuMDx Group Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
How is each segment of the global molecular diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
What are the key developmental strategies implemented by the major players to sustain in the competitive market?
What are the key regulatory implications in developed and developing regions for molecular diagnostics?
Who are the leading players with significant offerings to the global molecular diagnostics market? What is the current market dominance for each of these leading players?
What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which molecular diagnostic product type has the most promising growth?
What are the key applications in the global molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
What are the major technologies that are employed in the global molecular diagnostics market? Which is the dominating technology?
Who are the primary end-users of the global molecular diagnostics market? Which is the fastest-growing end-user segment in the global molecular diagnostics market?
Who are the key manufacturers in the global molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular diagnostics application and end user dominate these regions?
What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
Which technologies are anticipated to break through the current molecular diagnostic regime?
Which companies are anticipated to be highly disruptive in the future and why?
What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will these enhance the reimbursement scenario?
What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are these gaps being tackled?
Key Topics Covered:
1.1 Product Definition
1.1.2 Inclusion and Exclusion
1.2 Market Overview
1.3 Historical Perspective
1.4 Significant Technologies
1.5 Classification of Molecular Diagnostics
1.6 Global Footprint
1.7 Global Molecular Diagnostics Market Size and Forecast - Realistic, Optimistic, and Conservative Growth Scenario
1.7.1 Realistic Growth Scenario
1.7.2 Conservative Growth Scenario
1.8 Future Potential
1.8.1 Optimistic Growth Scenario
1.9 Market Dynamics
1.9.1 Impact Analysis
1.9.2 Market Drivers
126.96.36.199 A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
188.8.131.52 Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
184.108.40.206 Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
220.127.116.11 Significant External Funding for Executing Research and Development Exercises
1.9.3 Market Restraints
18.104.22.168 Uncertain Reimbursement Scenario
22.214.171.124 Lack of High-Complexity Testing Centers
126.96.36.199 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
1.9.4 Market Opportunities
188.8.131.52 Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
184.108.40.206 Rise of Next-Generation Ultrasensitive Molecular Diagnostics
220.127.116.11 Novel Revenue Streams
1.1 COVID-19 Impact on Global Molecular Diagnostics Market
1.10.1 Impact on Market Size
1.10.2 Impact on Molecular Diagnostic Practices
1.11 Competitive Landscape
1.11.2 Synergistic Activities
1.11.3 Product Launches and Upgradations
1.11.4 Business Expansion
1.11.5 Market Share Analysis, by Company
1.11.6 Growth Share Analysis, by Technology
1.12 Industry Insights
1.12.1 Legal Requirements and Framework in the U.S.
1.12.2 FDA Regulations
1.12.3 Legal Requirements and Framework in Europe
1.12.4 Legal Requirements and Framework in Asia-Pacific
18.104.22.168.1 Pharmaceuticals and Medical Devices Agency (PMDA)
22.214.171.124.2 Ministry of Health, Labour, and Welfare (MHLW)
1.13 Patent Analysis
1.13.1 Patent Filing Trend
2.1.2 Kits and Consumables
2.1.3 Software and Other Products
3 Testing Location
3.1.1 Laboratory Testing
3.1.2 Point-of-Care Testing
4.1.1 Polymerase Chain Reaction (PCR)
4.1.2 Next-Generation Sequencing
4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
4.1.5 In-Situ Hybridization (ISH)
4.1.6 Immunohistochemistry (IHC)
4.1.7 Other Technologies
5.1.1 Core Molecular Diagnostics
126.96.36.199 Infectious Disease
188.8.131.52.1 Respiratory Infections
184.108.40.206.1.1 Influenza A and B
220.127.116.11.1.2 COVID-19 Infections
18.104.22.168.1.3 Respiratory Syncytial Virus
22.214.171.124.1.4 Mycoplasma Infections
126.96.36.199.1.6 Other Respiratory Infections
188.8.131.52.2 Sexual Transmitted Infections(STI)
184.108.40.206.2.1 Common Pathogens Associated with Sexually Transmitted Infection
220.127.116.11.2.2 Hepatitis B
18.104.22.168.2.5 Herpes Simplex Virus
22.214.171.124.2.6 Neisseria Gonorrhoeae
126.96.36.199.2.7 Other STIs
188.8.131.52 Hereditary Genetic Testing
184.108.40.206 Blood Donor Screening
220.127.116.11 Human Leukocyte Antigen (HLA) Testing
18.104.22.168 Other Molecular Diagnostics Applications
5.1.2 Reproductive Genetics
22.214.171.124 Carrier Screening
126.96.36.199 Non-Invasive Pre-Natal Testing (NIPT)
188.8.131.52 Pre-Implantation Genetic Testing
184.108.40.206 Infertility Genetic Testing
5.1.3 Companion Diagnostics (CDx)
5.1.4 Liquid Biopsy
5.1.5 Other Applications
220.127.116.11 Hospitals, by Respiratory Infections Molecular Diagnostics Market
18.104.22.168.1 Hospitals, by Influenza A and B
22.214.171.124.2 Hospitals, by COVID-19 Infections
126.96.36.199.3 Hospitals, by Respiratory Syncytial Virus
188.8.131.52.4 Hospitals, by Mycoplasma Infection
184.108.40.206.5 Hospitals, by Pertussis
220.127.116.11.6 Hospitals, by Other Respiratory Infections
18.104.22.168 Hospitals Sexually Transmitted Infections (STIs) Market
22.214.171.124.1 Hospitals, by Hepatitis B
126.96.36.199.2 Hospitals, by HIV AIDS
188.8.131.52.3 Hospitals, by HPV
184.108.40.206.4 Hospitals, by Herpes Simplex Virus(HSV)
220.127.116.11.5 Hospitals, by Neisseria gonorrhoeae
18.104.22.168.6 Hospitals, by Other STIs
6.1.2 Diagnostic Centers
22.214.171.124 Diagnostic Centers, by Respiratory Infections Molecular Diagnostics Market
126.96.36.199.1 Diagnostic Centers, by Influenza A and B
188.8.131.52.2 Diagnostic Centers, by COVID-19 Infections
184.108.40.206.3 Diagnostic Centers, by Respiratory Syncytial Virus
220.127.116.11.4 Diagnostic Centers, by Mycoplasma Infection
18.104.22.168.5 Diagnostic Centers, by Pertussis
22.214.171.124.6 Diagnostic Centers, by Other Respiratory Infections
126.96.36.199 Diagnostic Centers Sexually Transmitted Infections (STIs) Market
188.8.131.52.1 Diagnostic Centers, by Hepatitis B
184.108.40.206.2 Diagnostic Centers, by HIV AIDS
220.127.116.11.3 Diagnostic Centers, by HPV
18.104.22.168.4 Diagnostic Centers, by Herpes Simplex Virus(HSV)
22.214.171.124.5 Diagnostic Centers, by Neisseria gonorrhoeae
126.96.36.199.6 Diagnostic Centers, by Other STIs
6.1.3 Out-Patient Clinics/General Practitioners
188.8.131.52 Out-Patient Clinics/General Practitioners, by Respiratory Infections Molecular Diagnostics Market
184.108.40.206.1 Out-Patient Clinics/General Practitioners, by Influenza A and B
220.127.116.11.2 Out-Patient Clinics/General Practitioners, by COVID-19 Infections
18.104.22.168.3 Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus
22.214.171.124.4 Out-Patient Clinics/General Practitioners, by Mycoplasma Infection
126.96.36.199.5 Out-Patient Clinics/General Practitioners, by Pertussis
188.8.131.52.6 Out-Patient Clinics/General Practitioners, by Other Respiratory Infections
184.108.40.206 Out-Patient Clinics/General Practitioners Sexually Transmitted Infections (STIs) Market
220.127.116.11.1 Out-Patient Clinics/General Practitioners, by Hepatitis B
18.104.22.168.2 Out-Patient Clinics/General Practitioners, by HIV AIDS
22.214.171.124.3 Out-Patient Clinics/General Practitioners, by HPV
126.96.36.199.4 Out-Patient Clinics/General Practitioners, by Herpes Simplex Virus(HSV)
188.8.131.52.5 Out-Patient Clinics/General Practitioners, by Neisseria gonorrhoeae
184.108.40.206.6 Out-Patient Clinics/General Practitioners, by Other STIs
6.1.4 Research Laboratories
220.127.116.11 Research Laboratories, by Respiratory Infections Molecular Diagnostics Market
18.104.22.168.1 Research Laboratories, by Influenza A and B
22.214.171.124.2 Research Laboratories, by COVID-19 Infections
126.96.36.199.3 Research Laboratories, by Respiratory Syncytial Virus
188.8.131.52.4 Research Laboratories, by Mycoplasma Infection
184.108.40.206.5 Research Laboratories, by Pertussis
220.127.116.11.6 Research Laboratories, by Other Respiratory Infections
18.104.22.168 Research Laboratories Sexually Transmitted Infections (STIs) Market
22.214.171.124.1 Research Laboratories, by Hepatitis B
126.96.36.199.2 Research Laboratories, by HIV AIDS
188.8.131.52.3 Research Laboratories, by HPV
184.108.40.206.4 Research Laboratories, by Herpes Simplex Virus(HSV)
220.127.116.11.5 Research Laboratories, by Neisseria gonorrhoeae
18.104.22.168.6 Research Laboratories, by Other STIs
6.1.5 Other End Users
8 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/lkdydl
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900